QuidelOrtho Corporation (QDEL)

SAN DIEGO , Aug. 21, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the completion of a series of related transactions to refinance its debt structure and support future growth. Through these transactions, the Company extended its debt maturities and reduced required amortization payments.

SAN DIEGO , Aug. 21, 2025 /PRNewswire/ -- With classrooms once again filled and respiratory virus season beginning, QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, is sharing timely public health insights from Dr. Jonathan Temte, Professor of Family Medicine and Community Health at the University of Wisconsin-Madison. In this 50th episode of QuidelOrtho Science Bytes, Dr. Temte outlines the seasonal challenges posed by influenza, RSV, COVID-19 and vaccine-preventable diseases such as measles and whooping cough.

SAN DIEGO , Aug. 19, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, welcomes Erich Wolff as Executive Vice President, Strategy & Corporate Development. In this role, Mr.

Initiative to expand testing access to underserved U.S. communities SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- QuidelOrtho Corporation has launched a Certified Analyzer Program, an innovative initiative designed to expand access to high-quality diagnostic testing in rural and community hospitals across the United States. Tailored for clinics, physician office labs and small hospitals with fewer than 100 beds, the program offers certified VITROS™ analyzers that deliver proven reliability and quality results, with award-winning service, at a fraction of the cost.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

QDEL stock rises 12.8% after Q2 earnings beat. Adjusted margins improve amid soft revenue and ongoing business headwinds.

QuidelOrtho Corporation (NASDAQ:QDEL ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Brian J. Blaser - President, CEO & Director Joseph M.

QuidelOrtho (QDEL) Fiscal Q2 EPS Beats

― Labs revenue grew 4% as reported and 5% in constant currency ― ― Adjusted EBITDA margin improved by 330 basis points; Achieved $100 million annualized cost savings from initiatives announced in 2024 ― ― Company reiterates full-year 2025 financial guidance ― Second Quarter 2025 Results (all comparisons are to the prior year period) Total revenue was $614 million, as reported Non-respiratory revenue was $567 million, a decrease of 2% both as reported and in constant currency; excluding Donor Screening, non-respiratory revenue grew 1% in constant currency Labs revenue grew 4% as reported and 5% in constant currency Immunohematology revenue grew 4% as reported and 3% in constant currency Respiratory revenue was $47 million, a 20% decrease primarily driven by lower COVID-19 revenue GAAP and non-GAAP operating expenses1 decreased 9%, driven by the Company's cost-savings initiatives GAAP net loss margin was (42%); GAAP operating margin was (29%); adjusted EBITDA margin was 17%, a 330 basis point improvement GAAP diluted loss per share was $3.77; adjusted diluted earnings per share ("EPS") was $0.12 SAN DIEGO , Aug. 5, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the second quarter ended June 29, 2025. "Our second quarter results demonstrate our continuing commitment to commercial and operational execution," said Brian J.

SAN DIEGO , July 29, 2025 /PRNewswire/ -- QuidelOrtho earned three awards and top rankings in the 2025 IMV ServiceTrak™ Awards, presented at the Association for Diagnostics & Laboratory Medicine, recognizing excellence in customer satisfaction across key performance areas. Awards: Chemistry Best overall system performance Integrated Systems Best overall system performance Best overall service Top Rankings: QuidelOrtho received top rankings in several key categories for Integrated Systems, including: #1 Overall Net Promoter Score (NPS) by Manufacturer #1 Overall Manufacturer Performance #1 Overall Service Engineer Performance #1 Overall Training Performance QuidelOrtho invested in initiatives focused on what customers value most, driving significant advances in reliability, product quality and service.

Episode 49 of QuidelOrtho Science Bytes explores substance use trends, the limits of Narcan, and the evolving challenges facing emergency departments SAN DIEGO , July 24, 2025 /PRNewswire/ -- In emergency care settings, every second counts. Early drug detection not only improves clinical decision-making, it can be the difference between life and death.

SAN DIEGO , July 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its second quarter 2025 ended June 29, 2025, after the market close on Tuesday, August 5, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m.

QuidelOrtho Announces Featured ADLM Session SAN DIEGO , July 17, 2025 /PRNewswire/ -- How can actionable, Six Sigma insights improve lab performance? In a featured session at the Association for Diagnostics & Laboratory Medicine (ADLM) meeting, QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") and a panel of experts will share how QuidelOrtho's Six Sigma tools and real lab data can drive quality outcomes.

Gastrointestinal biomarker tests enhance patient diagnosis of IBD and pancreatic insufficiency on leading clinical chemistry platforms SAN DIEGO , July 14, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") and BÜHLMANN Laboratories AG today announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems as an MPA. Both particle-enhanced turbidimetric immunoassays, the fCAL turbo assay for fecal calprotectin measurement aids in the diagnosis of inflammatory bowel disease (IBD) and its differentiation from irritable bowel syndrome, and the fPELA turbo assay for fecal pancreatic elastase aids in the determination of pancreatic insufficiency.

BWMX, QDEL and ERO made it to the Zacks Rank #1 (Strong Buy) value stocks list on July 8, 2025.